PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics

被引：0
|
作者：
Powles, T. B. [1 ]
van der Heijden, M. S. [2 ]
Balar, A. V. [3 ]
O'Donnell, P. [4 ]
Massard, C. [5 ]
Walker, J. [6 ]
Gupta, A. [7 ]
Angra, N. [7 ]
Cairns, J. [8 ]
Turriziani, B. [6 ]
Rebelatto, M. C. [7 ]
Scott, M. [6 ]
Wildsmith, S. [6 ]
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands
[3] NYU, Dept Med, Perlmutter Canc Ctr, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA
[4] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[5] Gustave Roussy Canc Campus, DITEP, Villejuif, France
[6] AstraZeneca, Oncol R&D, Cambridge, England
[7] AstraZeneca, Oncol R&D, Gaithersburg, MD USA
[8] AstraZeneca, Stat, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13P
引用
收藏
页码：S1421 / S1421
页数：1
相关论文
共 50 条
  • [41] Urothelial Carcinoma with Sarcomatoid Transformation: An Analysis of PD-L1 Expression Status
    Gupta, Sounak
    Dashti, Nooshin K.
    Thapa, Prabin
    Hernandez, Loren Herrera
    Raghunathan, Aditya
    Sukov, William
    Jimenez, Rafael
    Boorjian, Stephen
    Frank, Igor
    Cheville, John
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 891 - 891
  • [42] PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives
    Gevaert, Thomas
    Cimadamore, Alessia
    Montironi, Rodolfo
    Eckstein, Markus
    CURRENT DRUG TARGETS, 2021, 22 (02) : 162 - 170
  • [43] Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications
    Germana, Emanuela
    Pepe, Ludovica
    Pizzimenti, Cristina
    Ballato, Mariagiovanna
    Pierconti, Francesco
    Tuccari, Giovanni
    Ieni, Antonio
    Giuffre, Giuseppe
    Fadda, Guido
    Fiorentino, Vincenzo
    Martini, Maurizio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
  • [44] Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Li, Han A.
    Regazzi, Ashely M.
    Lee, Chung-Han
    Funt, Samuel A.
    Bajorin, Dean
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF IMMUNOTHERAPY, 2021, 44 (07) : 248 - 253
  • [45] PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma
    Brown, Landon C.
    Zhu, Jason
    Labriola, Matthew K.
    Wu, Yuan
    Cheris, Sachica
    Liu, Xin
    Perkinson, Kathryn
    Su, Zuowei
    McCall, Shannon
    Huang, Jiaoti
    Foo, Wen-Chi
    Gupta, Rajan T.
    Armstrong, Andrew J.
    George, Daniel J.
    Harrison, Michael R.
    Zhang, Tian
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 509 - 513
  • [46] PD-L1 testing in urothelial bladder cancer: essentials of clinical practice
    Rouanne, Mathieu
    Radulescu, Camelia
    Adam, Julien
    Allory, Yves
    WORLD JOURNAL OF UROLOGY, 2021, 39 (05) : 1345 - 1355
  • [47] PD-L1 testing in urothelial bladder cancer: essentials of clinical practice
    Mathieu Rouanne
    Camélia Radulescu
    Julien Adam
    Yves Allory
    World Journal of Urology, 2021, 39 : 1345 - 1355
  • [48] Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer
    de Liano Lista, Alfonso Gomez
    van Dijk, Nick
    Oria de Rueda, Guillermo de Velasco
    Necchi, Andrea
    Lavaud, Pernelle
    Morales-Barrera, Rafael
    Alonso Gordoa, Teresa
    Maroto, Pablo
    Ravaud, Alain
    Duran, Ignacio
    Szabados, Bernadett
    Castellano, Daniel
    Giannatempo, Patrizia
    Loriot, Yohann
    Carles, Joan
    Anguera Palacios, Georgia
    Lefort, Felix
    Raggi, Daniele
    Goupil, Marine Gross
    Powles, Thomas
    Van der Heijden, Michiel S.
    EUROPEAN UROLOGY, 2020, 77 (02) : 269 - 276
  • [49] Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors
    Hwang, Inhwan
    Park, Inkeun
    Yoon, Shin-kyo
    Lee, Jae Lyun
    CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E122 - E133
  • [50] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345